Weidong Han

20.2k total citations · 6 hit papers
267 papers, 15.0k citations indexed

About

Weidong Han is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Weidong Han has authored 267 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Oncology, 98 papers in Molecular Biology and 67 papers in Immunology. Recurrent topics in Weidong Han's work include CAR-T cell therapy research (86 papers), Immune Cell Function and Interaction (42 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Weidong Han is often cited by papers focused on CAR-T cell therapy research (86 papers), Immune Cell Function and Interaction (42 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Weidong Han collaborates with scholars based in China, United States and Philippines. Weidong Han's co-authors include Yao Wang, Xiaobing Fu, Zhiqiang Wu, Yelei Guo, Hanren Dai, Xiaolei Li, Kaichao Feng, Jiejie Liu, Haojie Hao and Chuan Tong and has published in prestigious journals such as Science, The Lancet and Nucleic Acids Research.

In The Last Decade

Weidong Han

258 papers receiving 14.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

2020 940 citations Huabin He, Xuyan Shi et al. Science profile →
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

2020 719 citations Meixia Chen, Yan Zhang et al. profile →
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b

2015 547 citations Dongdong Ti, Chuan Tong et al. profile →
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

2020 293 citations Na Tang, Chen Cheng et al. JCI Insight profile →
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer

2021 253 citations Kaichao Feng, Weidong Han et al. profile →
Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation

2024 83 citations Weidong Han et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Weidong Han	7.4k	6.2k	4.3k	2.3k	2.0k	267	15.0k
Maurilio Ponzoni	6.6k 0.9×	4.7k 0.8×	3.8k 0.9×	610 0.3×	1.4k 0.7×	296	16.6k
Ellen Puré	4.4k 0.6×	5.5k 0.9×	5.1k 1.2×	973 0.4×	2.4k 1.2×	173	15.4k
Dario Campana	7.6k 1.0×	5.2k 0.8×	7.7k 1.8×	1.0k 0.4×	1000 0.5×	287	22.5k
Udai S. Kammula	14.0k 1.9×	4.2k 0.7×	10.2k 2.4×	1.1k 0.5×	985 0.5×	89	18.2k
Claudio Bordignon	5.9k 0.8×	5.9k 1.0×	5.0k 1.2×	996 0.4×	364 0.2×	222	14.1k
Rupert Handgretinger	5.4k 0.7×	5.3k 0.9×	7.0k 1.6×	472 0.2×	1.0k 0.5×	493	19.0k
Mariusz A. Wasik	4.9k 0.7×	3.2k 0.5×	3.4k 0.8×	551 0.2×	696 0.3×	187	10.4k
Katayoun Rezvani	5.5k 0.7×	2.8k 0.5×	4.9k 1.1×	992 0.4×	722 0.4×	216	11.2k
Ignacio Melero	15.8k 2.1×	6.6k 1.1×	16.8k 3.9×	2.1k 0.9×	2.4k 1.2×	396	28.2k
Robert H. Vonderheide	15.2k 2.0×	6.9k 1.1×	14.2k 3.3×	1.6k 0.7×	3.2k 1.6×	224	25.0k

Countries citing papers authored by Weidong Han

Since Specialization

Citations

This map shows the geographic impact of Weidong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidong Han more than expected).

Fields of papers citing papers by Weidong Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weidong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidong Han. The network helps show where Weidong Han may publish in the future.

Co-authorship network of co-authors of Weidong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Weidong Han. A scholar is included among the top collaborators of Weidong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weidong Han. Weidong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rong, Guanghua, et al.. (2025). Epi‐Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future Directions. PubMed. 4(5). e70023–e70023.

Han, Lu, Zhiqiang Wu, Yao Wang, et al.. (2025). CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation. Cellular and Molecular Immunology. 22(8). 935–948. 1 indexed citations

Liu, Jiejie, Tiance Wang, Yan Zhang, et al.. (2024). Manganese boosts natural killer cell function via cGAS–STING mediated UTX expression. SHILAP Revista de lepidopterología. 5(9). e683–e683. 5 indexed citations

Liu, Yang, Meng Zhang, Xia Xiao, et al.. (2024). Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy. International Immunopharmacology. 130. 111761–111761. 6 indexed citations

Dong, Liang, Zhi Cao, Meixia Chen, et al.. (2024). Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. Nature Communications. 15(1). 6970–6970. 7 indexed citations

Zhang, K., et al.. (2023). Construction of a predictive model for osteoporosis risk in men: using the IOF 1-min osteoporosis test. Journal of Orthopaedic Surgery and Research. 18(1). 770–770. 2 indexed citations

Yang, Yuzhuo, Xin Lin, Yao Wang, et al.. (2023). IL-6 translation is a therapeutic target of human cytokine release syndrome. The Journal of Experimental Medicine. 220(11). 14 indexed citations

Wang, Yao, Chuan Tong, Yuting Lu, et al.. (2023). Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduction and Targeted Therapy. 8(1). 409–409. 35 indexed citations

Guo, Yelei, Chuan Tong, Liping Su, et al.. (2022). CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. Blood Advances. 6(8). 2695–2699. 22 indexed citations

10.

Wang, Chunmeng, Yang Liu, Liang Dong, et al.. (2021). Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. Clinical Cancer Research. 27(10). 2782–2791. 29 indexed citations

11.

Li, Xiaolei, Hanren Dai, Xian Li, et al.. (2021). Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cellular and Molecular Immunology. 19(1). 122–124. 1 indexed citations

12.

Wang, Yao, Yang Liu, Chuan Tong, et al.. (2021). Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia. 36(1). 189–196. 64 indexed citations

13.

Feng, Kaichao, Yang Liu, Qingming Yang, et al.. (2020). Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. Journal for ImmunoTherapy of Cancer. 8(1). e000367–e000367. 89 indexed citations

14.

Tang, Na, Chen Cheng, Xingying Zhang, et al.. (2020). TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 5(4). 293 indexed citations breakdown →

15.

Mei, Qian, Wenying Zhang, Yang Liu, et al.. (2020). Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. Clinical Cancer Research. 26(17). 4521–4530. 17 indexed citations

16.

He, Huabin, Xuyan Shi, Yupeng Wang, et al.. (2020). Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 368(6494). 940 indexed citations breakdown →

17.

Li, Xiang, Yan Zhang, Meixia Chen, et al.. (2017). Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy. Clinical Cancer Research. 23(20). 6031–6043. 45 indexed citations

18.

Guo, Yelei, Kaichao Feng, Yang Liu, et al.. (2017). Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clinical Cancer Research. 24(6). 1277–1286. 196 indexed citations

19.

Wang, Chunmeng, Zhiqiang Wu, Yao Wang, et al.. (2016). Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clinical Cancer Research. 23(5). 1156–1166. 261 indexed citations

20.

Mei, Qian, Xiang Li, Kang Zhang, et al.. (2016). Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway. Clinical Cancer Research. 23(2). 575–586. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact